INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.37555826228177025 | N/A |
Market Cap | $34.56M | N/A |
Shares Outstanding | 92.02M | 1.28% |
Employees | 0 | N/A |
Shareholder Equity | 19.62M | -30.67% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 128.26 | N/A |
P/B Ratio | 1.76 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.3094 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $269.45K | N/A |
Earnings | -$6.07M | N/A |
Gross Margin | 0.8883 | N/A |
Operating Margin | -26.31 | N/A |
Net income margin | -22.52 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $14.55M | N/A |
Total Debt | $494.46K | N/A |
Cash on Hand | $5.29M | N/A |
Debt to Equity | 0.0653 | 9.83% |
Cash to Debt | $10.69 | -30.64% |
Current Ratio | $6.20 | -36.31% |